Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pharmaceutical"


25 mentions found


There is no proof that spike proteins created in response to mRNA vaccines are harmful to the body, scientists have told Reuters. He said: “We made a big mistake… we thought the spike protein was a great target antigen, (but) we never knew the spike protein itself was a toxin and a pathogenic protein.”He speculated that COVID-19 shots could lead to cardiovascular problems and infertility, because “by vaccinating people we are inadvertently inoculating them with a toxin” (timestamp 8.27). Crucially, these spike proteins declined in the subsequent weeks, and no spike proteins were detected after the second injection. By contrast, people who catch the coronavirus and become infected with COVID-19 can develop high levels of the spike protein that can cause adverse effects. This includes pharmacologist Sabina Vohra-Miller (www.vohramillerfoundation.ca/), who produced a Twitter infographic explaining that spike proteins from the vaccine are harmless and do not impact infertility (here).
Persons: immunologist Byram, Alex Pierson, Hal Turner, Rather, David Walt, , Walt, Sabina Vohra, Miller, Read Organizations: Reuters, Health, Japan’s Pharmaceuticals, Medical Devices Agency, PFIZER, Pfizer, Pharmaceutical, Economic Area Locations: Canadian, Japan, United States
Japanese shares track Nasdaq higher, drug makers shine
  + stars: | 2021-06-15 | by ( Reuters Staff | ) www.reuters.com sentiment -0.94   time to read: +2 min
TOKYO, June 15 (Reuters) - Japanese shares closed higher on Tuesday, buoyed by technology and growth-oriented stocks following a strong finish on the Nasdaq overnight, while drug makers extended their gains. “Today’s strong market finish is simply a reaction to the gains in the Nasdaq overnight,” said Jun Morita, general manager of the research department at Chibagin Asset Management. Eisai shares have been volatile since the company’s Alzheimer’s drug, developed in partnership with Biogen Inc , got a nod from U.S. regulators last week. The U.S. Food and Drug Administration is facing mounting criticism over the drug approval. Growth stocks led the gains after Nasdaq shares outperformed on Wall Street, with the Topix Growth Index rising 1.09%, compared with 0.53% gains in value shares.
Persons: , , Jun Morita, Eisai, Takeda, Junko Fujita, Hideyuki Sano, Shailesh Kuber, Subhranshu Sahu Organizations: Nasdaq, Nikkei, U.S, U.S . Federal, Chibagin Asset Management, “ Investors, , Tokyo Stock, Eisai, Biogen Inc, U.S . Food, Drug Administration, Takeda Pharmaceutical, Toyota Motor Locations: TOKYO, U.S ., U.S, Japan, Tokyo
TOKYO, June 15 (Reuters) - Japanese shares rallied on Tuesday, with the broad Topix index hitting a two-month high, as property shares extended their gains while technology and growth-oriented firms enjoyed a boost from strong gains in the Nasdaq. As of 0045 GMT, the Nikkei was up 0.88% at 29,419.36, having hit its highest level since early May while the broader Topix rose 0.54% to 1,970.42, reaching its highest levels since early April. Real estate firms were among the best performers with gains of 1.6% as they continued to benefit from hopes of economic reopenings as vaccine roll-outs accelerate. Growth shares led the gains after Nasdaq shares outperformed on Wall Street, with Topix Growth Index rising 0.8%, compared with 0.3% gains in value shares. Takeda Pharmaceutical, which is handling supply of Novavax’s vaccine in Japan, rose 1.5% after clinical tests showed the U.S. firm’s COVID-19 vaccine as having 90% efficacy.
Persons: drugmaker Eisai, firm’s, Hideyuki Sano, Shailesh Kuber Organizations: Nasdaq, Nikkei, U.S, U.S . Federal, Sumitomo Realty, Development, Mitsubishi Estate, Mitsui Fudosan, Olympus, Pharmaceutical, Mitsui, tec Locations: TOKYO, U.S ., Japan
REUTERS/Dado Ruvic/Illustration/File PhotoAnglo-Swedish drugmaker AstraZeneca (AZN.L) said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus. AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported. AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease. The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection. Rivals Regeneron Pharmaceuticals Inc (REGN.O) and Eli Lilly & Co (LLY.N) have both developed monoclonal antibody therapies which have been authorised for use in the United States to treat patients infected with the virus.
Persons: Dado Ruvic, AZD7442, Eli Lilly Organizations: Astra, AstraZeneca, REUTERS, Rivals Regeneron Pharmaceuticals Inc, European Medicines Agency, GlaxoSmithKline, Vir Biotechnology Inc, Lonza, U.S ., U.S, Thomson Locations: Swedish, United States, Celltrion, Swiss, Portsmouth , New Hampshire
Only one of the 10 medical cannabis companies in New York isn't owned by a multistate operator. Analysts at Stifel said they expect adult-use cannabis sales to start in late 2022, and that the state's market could exceed $5 billion. Cronos Group, a Canadian cannabis company backed by Altria, said in June that it's making a "strategic investment" in private US cannabis company PharmaCann, which has operations in New York. AP Photo/Julio Cortez, FileCompanies eyeing New York's adult-use market have been carefully watching the legislation for months now. The company announced in late March that it had agreed to purchase private New Jersey-based cannabis company Garden State for $101 million.
Persons: Stifel, Altria, New York Jeffrey Schultz, Feuerstein Kulick, Schultz, it's, MedMen, We've, Howard Schacter, Hillary Peckham, Peckham, she's, Cronos, Bill Doran, Benesch Friedlander, Doran, Moelis, Cowen, Vivien Azer, Matilde Campodonico, Norman Birenbaum, Birenbaum, Julio Cortez, Ayr, Jennifer Drake, Boris Jordan, We're, Joe Bayren, Ben Kovler, Andrew Cuomo Organizations: Capital Advisors, Cresco Labs, Green Thumb Industries, Fiorello Pharmaceuticals, Cronos, New York, iAnthus, NY, Columbia, Labs, Health, MedMen, Left Coast Ventures, Moelis, Company, Wellness Holdings, AP, Care, Companies, Ayr Wellness, Garden State, Thumb, Gov Locations: York, New York, MedMen's New York, Canadian, PharmaCann, New, NY, Caliva, Ayr, New Jersey, Garden
Vet IPO shrugs off animal-free trend
  + stars: | 2021-06-14 | by ( ) www.reuters.com sentiment -1.00   time to read: +1 min
A cow opens its mouth during feeding at the Johann Dairy farm in Fresno, California, U.S. September 10, 2020. Livestock health company Huvepharma, which makes health and nutrition additives for cows, pigs and other animals, announced on Monday it will list in Amsterdam. Huvepharma’s enzymes, food additives and vaccines produced EBITDA of 167 million euros in 2020 on sales of 588 million euros. The offering will test the appetite of investors who have pushed up the valuations of plant-based food brands like newly-listed Oatly (OTLY.O) read more . Though more people are embracing vegan and vegetarian diets, Huvepharma reckons the impact on demand for food animal products will be limited.
Persons: Afanasieva Organizations: Johann, Livestock, Dechra Pharmaceuticals, Shareholders Locations: Fresno , California, U.S, Amsterdam, London, Refinitiv, Paris
Brazil reports 1,129 new COVID-19 deaths, nearly 40,000 cases
  + stars: | 2021-06-13 | by ( ) www.reuters.com + 1.00   time to read: 1 min
Healthcare & Pharmaceuticals · 8:05 PM UTC AstraZeneca shots have good risk-benefit profile for over 60s, says EMA officialThe head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca's (AZN.L) coronavirus vaccine had a favourable risk-benefit profile for all age groups and particularly for those aged over 60.
Persons: regulator's COVID Organizations: Pharmaceuticals, AstraZeneca
FTSE 100 eyes best week in over a month as economy strengthens
  + stars: | 2021-06-11 | by ( Devik Jain | ) www.reuters.com sentiment -0.78   time to read: +2 min
FILE PHOTO: People walk through the lobby of the London Stock Exchange in London, Britain August 25, 2015. REUTERS/Suzanne Plunkett/File photoThe blue-chip index rose 0.6%, with precious metal miners and base metal miners jumping 1.8% and 1.5%, respectively. The index was up 0.8% for the week, its biggest percentage gain since the week ending May 7. In April alone, output rose by 2.3%, marking the fastest growth since July and helped by a rapid growth in the services sector. Auto Trader Group gained 1.5% after brokerages raised their price targets on the online car marketplace’s stock.
Persons: Suzanne Plunkett, there’s, we’ve, , Danni Hewson, AJ Bell, Robert Walters, brokerages, Informa, JP Morgan Organizations: Reuters, London Stock Exchange, REUTERS, Pharmaceutical, AstraZeneca, Sanne, Cinven, Auto Trader Locations: London, Britain
Mining, healthcare stocks boost FTSE 100 as economy strengthens
  + stars: | 2021-06-11 | by ( Reuters Staff | ) www.reuters.com + 0.90   time to read: +1 min
The blue-chip index rose 0.3%, with precious metal miners and base metal miners jumping 2% and 1.4%, respectively. Pharmaceutical stocks also rose, with AstraZeneca leading the gains. The domestically focused mid-cap FTSE 250 index advanced 0.3%. In April alone, output rose by 2.3%, marking the fastest growth since July. (Reporting by Devik Jain in Bengaluru; editing by Uttaresh.V)
Persons: Devik Jain Organizations: Pharmaceutical, AstraZeneca, Sanne, Cinven Locations: Bengaluru
Healthcare & Pharmaceuticals · 4:41 AM UTC ‘Extraordinary times, extraordinary measures’: U.S. approach to vanquish pandemicThe United States will continue to press for a waiver of intellectual property rights for COVID-19 vaccines and treatments even as it and other Group of Seven rich nations sharply expand donations of vaccines to poorer countries.
Organizations: Pharmaceuticals Locations: States
Take a look at some of the biggest movers in the premarket:Snowflake (SNOW) – Snowflake shares fell 3.7% in premarket trading, following the cloud computing company's presentation of financial targets at its Investor Day meeting. Chewy (CHWY) – Chewy earned 9 cents per share for its latest quarter, compared to consensus forecasts for a 3 cents per share loss. Royal Caribbean lost 1.3% in premarket trading. Callaway slid 3.7% in premarket trading, while Apollo surged 11.9%. Livent (LTHM) – The lithium power specialist's shares fell 2% in the premarket after announcing a public offering of 13 million shares at $17.50 per share.
Persons: Snowflake, – Chewy, Chewy, Buster's, Dave, Bernstein, – Tesla, Goldman Sachs, – Callaway, GrubHub, Callaway Organizations: Vertex Pharmaceuticals, Royal, Royal Caribbean, UBS, Food, AMC Entertainment, GameStop, Clover Health, AMC, Plaid, American Airlines, Airlines, Aerospace, Callaway, GrubHub, Apollo Medical, Apollo Locations: Royal Caribbean, Fremont , California, ELY, Israel
Check out the companies making headlines in midday trading. Dave & Buster's — Dave & Buster's shares fell about 2% midday after trading higher in premarket action. On Thursday, the company reported first-quarter earnings of 40 cents per share, surprising analysts who expected a loss of 16 cents per share. Reddit favorites — Stocks popular among retail investors flocking to Reddit's WallStreetBets forum were volatile in midday trading after massive rallies in recent weeks. Meanwhile, GameStop shares declined more than 2%, ContextLogic shares fell more than 5% and shares of Clean Energy Fuels slid nearly 2.5%.
Persons: Buster's, Dave, Biogen, Bernstein, , — CNBC's Pippa Stevens, Yun Li, Maggie Fitzgerald, Jesse Pound, Tom Franck Organizations: Chewy, New York Stock Exchange, Vertex Pharmaceuticals, Wall, Drug Administration, RBC, AMC Entertainment, Clover Health Investments, GameStop, Clean Energy Fuels Locations: Thursday's
U.S. charges Israeli traders in healthcare insider trading scheme
  + stars: | 2021-06-10 | by ( Jonathan Stempel | ) www.reuters.com sentiment -0.99   time to read: +2 min
U.S. prosecutors on Thursday unveiled criminal charges in Manhattan accusing two Israeli traders of illegal trading in several biotechnology and healthcare companies in connection with a sprawling international insider trading scheme. Tomer Feingold and Dov Malnik were accused in a 15-count indictment of securities fraud, wire fraud, tender offer fraud, concealment of a money laundering scheme, and conspiracy. The U.S. Securities and Exchange Commission filed related civil charges against Feingold and Malnik in March 2020. The other trader, identified in media reports as Marc Demane Debih from Geneva, pleaded guilty to 38 charges and cooperated in U.S. prosecutors' insider trading case against Telemaque Lavidas, a pharmaceutical executive. He had been among six people charged in four indictments in October 2019 over an insider trading scheme that prosecutors said generated tens of millions of dollars in illegal profit.
Persons: Tomer Feingold, Dov Malnik, Feingold, Audrey Strauss, Malnik, Benjamin Taylor, Darina Windsor, Marc Demane Debih, Telemaque Lavidas, Lavidas Organizations: Authorities, Ariad Pharmaceuticals Inc, Avanir Pharmaceuticals Inc, InterMune Inc, U.S . Securities, Exchange Commission, Malnik, SEC, Moelis, Centerview Partners, Thomson Locations: Manhattan, Geneva, Switzerland, U.S
UK stocks muted ahead of ECB meeting, U.S. inflation data
  + stars: | 2021-06-10 | by ( Sagarika Jaisinghani | ) www.reuters.com + 0.00   time to read: +2 min
REUTERS/Peter Nicholls/File photoLondon-listed stocks were subdued in early trading on Thursday as investors turned to a European Central Bank policy meeting and U.S. inflation data for cues on whether global central banks could start tapering monetary policy sooner than expected. The export-heavy FTSE 100 (.FTSE) rose 0.2%, tracking small gains in Asian stocks, while the mid-cap FTSE 250 (.FTMC) was down 0.3%. read morePersonal goods (.FTNMX402040) and insurance (.FTNMX303020) stocks were also among the biggest gainers by 0740 GMT. "There's a sense of every man for himself ahead of the U.S. inflation data this evening, a data point that has left markets in limbo," said Jeffrey Halley, a market analyst at OANDA. The ECB is expected to keep its policy guidance unchanged and publish updated euro area macroeconomic projections at its policy meeting later in the day.
Persons: Peter Nicholls, Jeffrey Halley, Patrick Drahi's Organizations: London Stock Exchange, REUTERS, European Central Bank, Pharmaceutical, AstraZeneca, ECB, CMC, BT, Thomson Locations: London, Britain, Scotland
Japan's Nikkei ends higher on economic rebound hopes; Eisai drags Topix
  + stars: | 2021-06-10 | by ( Reuters Staff | ) www.reuters.com sentiment -1.00   time to read: +2 min
TOKYO, June 10 (Reuters) - Japan’s Nikkei index closed higher on Thursday, as shipping firms rose on prospects of more economic reopenings and drugmakers were boosted by reports of government support. The Nikkei share average ended 0.34% higher at 28,958.56, while the broader Topix ticked down 0.02% to 1,956.73. Signs that more economies are reopening amid a steady vaccine rollout underpinned shipping firms, with Nippon Yusen jumping 3.65% to be the biggest gainer on the Nikkei. Rival drugmaker Shionogi rose 3.4% on a local media report that the firm plans to mass-produce its own COVID-19 vaccines. “Some people say their rally on economic reopenings would last only about two weeks.
Persons: Yoshihide Suga, , Fumio Matsumoto, Konan Shoji, Yoshiaki Murakami Organizations: Nikkei, Nippon, Japan, Eisai, Chugai Pharmaceutical, Ono Pharmaceutical, Okasan Securities, Konan Locations: TOKYO, U.S
Japanese shares rise, Eisai drops after 2 days of limit-up gains
  + stars: | 2021-06-10 | by ( Reuters Staff | ) www.reuters.com + 0.00   time to read: +2 min
Hopes of economic reopenings amid a steady vaccine rollout underpinned real-estate companies, railway operators and airline companies, though some of them started to lose momentum after a steady rally so far this month. Eisai dropped as much as 8.5% after two days of gains by daily limit after U.S. regulators approved the drug, developed by the firm and Biogen, for Alzheimer’s disease. Rival drugmaker Shionogi jumped 7.3% on a local media report that the firm plans to mass-produce its own COVID-19 vaccines. Tobu Railway and Keio Corp - operators of train network in Tokyo and its suburbs - gained 2.3% and 2%, respectively. “Some people say their rally on economic reopenings would last only about two weeks.
Persons: Eisai, Yoshihide Suga, drugmaker Shionogi, , Fumio Matsumoto, Konan Shoji, Yoshiaki Murakami, Hideyuki Sano, Sherry Jacob, Phillips Organizations: Nikkei, Chugai Pharmaceutical, Ono Pharmaceutical, Tokyo Stock, Mitsubishi Estate, Tobu Railway, Keio Corp, Okasan Securities, Konan Locations: TOKYO, Japan, Tokyo
Cannabis private-equity firm Merida Capital is raising a $250 million fund. One of the most prolific investment firms in the cannabis industry is raising its fourth fund in five years, Insider has learned. The fourth fund will build on Merida's track record of investing in both publicly traded and startup cannabis companies, Baruchowitz said. Merida's first fund returned 200% to investors, Baruchowitz said, and he expects to generate a 600% return in his new fund. Employees tend to medical cannabis plants at Pharmocann, an Israeli medical cannabis company in northern Israel.
Persons: Mitch Baruchowitz, Baruchowitz, Dan Lipton, he's, Merida's, It's, Lipton, Amir Cohen, He's Organizations: Merida Capital, IV, Merida Capital Holdings, Merida's, Asset Management, Navy Capital, Nasdaq, Dharma Pharmaceuticals, Green Thumb Industries, Employees, Reuters Locations: Merida, GrowGeneration, Pharmocann, Israel
The pet-product retailer reported first-quarter earnings of 9 cents per share on revenue of $2.14 billion. Dave & Buster's — Dave & Buster's shares jumped 5% in extended trading after the restaurant and entertainment company reported first-quarter earnings topping analysts' expectations. Dave & Buster's saw quarterly earnings of 40 cents per share, while analysts projected a loss of 16 cents per share, according to Refinitiv. The company's first-quarter revenue also beat the Street's projections. AMC Entertainment — Shares of AMC Entertainment dropped 1% in extended trading after retail favorites hit a wall during the regular session.
Persons: Wall, Buster's, Dave Organizations: New York Stock Exchange, Chewy Inc, Pharmaceuticals, Vertex Pharmaceuticals, AMC, AMC Entertainment Locations: New York, U.S
Vertex cystic fibrosis treatment gets U.S. approval for use in 6-11 year olds
  + stars: | 2021-06-09 | by ( Reuters Staff | ) www.reuters.com sentiment -0.98   time to read: +1 min
FILE PHOTO: A U.S. flag flies in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder(Reuters) -Vertex Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its cocktail therapy, Trikafta, to treat cystic fibrosis in children aged between 6 to 11. The drug Trikafta, approved in 2019 to treat 12 years and older, is expected to reach about 1,500 newly eligible children in the United States, the company said. Vertex has submitted applications for use of the cocktail therapy in children aged 6 through 11 years to the European Medicines Agency and the Medicines & Healthcare Products Regulatory Agency. The company also plans to file for the expanded use in Switzerland, Australia and Israel this year.
Persons: Brian Snyder Organizations: Vertex Pharmaceuticals, REUTERS, Reuters, Vertex Pharmaceuticals Inc, U.S . Food, Drug Administration, European Medicines Agency, Medicines & Healthcare Products Regulatory Agency Locations: Boston , Massachusetts, U.S, United States, Switzerland, Australia, Israel
Vertex cystic fibrosis treatment gets U.S. nod for use in children aged 6-11
  + stars: | 2021-06-09 | by ( Dania Nadeem | ) www.reuters.com sentiment -0.53   time to read: +1 min
FILE PHOTO: A U.S. flag flies in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder(Reuters) -Vertex Pharmaceuticals Inc said the U.S. Food and Drug Administration has approved the expanded use of its Trikafta cocktail therapy to treat cystic fibrosis (CF) in children aged 6 to 11, making it the first approved treatment for CF in the age group. The treatment, currently priced at $311,503 per year, targets a defective protein responsible for the rare, life-threatening disease. CF is caused by a mutation of the CFTR gene, which regulates salt and water content in cells. Vertex has submitted applications for use of the cocktail therapy in children aged 6 to 11 to the European Medicines Agency and Britain’s medical regulator, the Medicines & Healthcare Products Regulatory Agency.
Persons: Brian Snyder, , Andrew Fein Organizations: Vertex Pharmaceuticals, REUTERS, Reuters, Vertex Pharmaceuticals Inc, U.S . Food, Drug Administration, CF, HC Wainwright, European Medicines Agency, Medicines & Healthcare Products Regulatory Agency Locations: Boston , Massachusetts, U.S, United States, Trikafta, Switzerland, Australia, Israel
Japan shares end lower on caution ahead of U.S. inflation data; Eisai jumps
  + stars: | 2021-06-09 | by ( Reuters Staff | ) www.reuters.com sentiment -0.96   time to read: +2 min
Financial firms and insurers declined after a retreat in long-term U.S. Treasury yields dampened the outlook for returns on their portfolios. The Nikkei share average ended 0.35% lower at 28,860.80, while the broader Topix was down 0.28% at 1,957.14. Right now though, “there’s a strong wait-and-see attitude overall in markets,” he said, adding that investors booked profits and squared positions ahead of the data. The Topix’s sea transport subsector was the biggest decliner, sliding 3.33%, following its surge to the highest in more than a decade. After Eisai, Sumitomo Realty and Development Co was the best performer on the Nikkei, with a 7.55% rally.
Persons: Eisai, , Masahiro Ichikawa, , Kawasaki Kisen, Lasertec, Tokyo Tatemono Organizations: Federal Reserve, Financial, Treasury, Nikkei, U.S, CPI, Sumitomo Mitsui DS Asset Management, Mitsui OSK Lines, Semiconductor, Pharmaceutical, Sumitomo Realty, Development, Mitsubishi Estate, . Airline ANA Holdings Locations: TOKYO, Tokyo
Japan shares slip on caution ahead of U.S. inflation data, Eisai extends gains
  + stars: | 2021-06-09 | by ( Reuters Staff | ) www.reuters.com sentiment -0.99   time to read: +1 min
Financial firms and insurers declined, as a retreat in long-term U.S. Treasury yields dampened the outlook for returns on their portfolios. Eisai Co, however, was poised to rise by the daily limit for a second session after its Alzheimer’s drug got a nod from U.S. regulators on Monday. The Nikkei share average fell 0.3% to 28,868.29 at the midday break, while the broader Topix slid 0.2% to 1,958.30. Right now though, “there’s a strong wait-and-see attitude overall in markets,” he said, adding investors booked profits and squared positions ahead of the data. The Topix’s sea transport subsector was the biggest decliner, sliding 2.8%, following its surge to the highest in more than a decade.
Persons: Eisai, , Masahiro Ichikawa, Organizations: Federal Reserve, Financial, Treasury, Nikkei, U.S, CPI, Sumitomo Mitsui DS Asset Management, Semiconductor, Air, Pharmaceutical Locations: TOKYO
Tech innovation is driving growth in healthcare, General Atlantic's Robbert Vorhoff told Insider. For "weeks now," General Atlantic's head of healthcare investments, has resumed travel to meet with portfolio companies as well as prospective investments. That excitement is evident in General Atlantic's latest investment decisions. The private equity firm has invested almost $1.4 billion in healthcare companies globally since the first quarter of 2020. And last August, General Atlantic's primary care startup Oak Street Health, went public with a $328 million IPO on the New York Stock Exchange.
Persons: Atlantic's Robbert Vorhoff, Vorhoff, Atlantic's, it's, We've, we've, I'd, General Atlantic's, JP Morgan Organizations: Vida Health, General Atlantic, Consumers, McKinsey, Healthcare, Atlantic, Centessa Pharmaceuticals, Nasdaq, Health, New York Stock Exchange, Wall, Citi, Deutsche Bank, Barclays Locations: Atlantic
China administered total of 777.88 mln doses of COVID-19 vaccines as of June 6
  + stars: | 2021-06-07 | by ( ) www.reuters.com sentiment -0.95   time to read: 1 min
Healthcare & Pharmaceuticals · 2:23 AM UTC Hundreds of former leaders urge G7 to vaccinate poor against COVID-19One hundred former presidents, prime ministers and foreign ministers have urged the Group of Seven (G7) rich nations to pay for global coronavirus vaccinations to help stop the virus mutating and returning as a worldwide threat.
Organizations: Pharmaceuticals, COVID
A widely shared video on social media incorrectly says the antimalarial drug hydroxychloroquine (HCQ) can be made at home using fruit peel. Seriously asking,” one social media user commented underneath the post. Reuters previously debunked a similar viral social media post falsely claiming that fruit peelings could be used to make quinine (here), a naturally occurring compound used to treat malaria. Read more about our work to fact-check social media posts here . Hydroxychloroquine is a synthetic drug and cannot be made at home using fruit peel.
Persons: , , Dr, Stephen Cochrane, Steve Hoare, David Brayden, Brayden, Read Organizations: Reuters, Chemistry, Queen’s University Belfast, Medicines, Association of, British Pharmaceutical Industry, University College Dublin, UCD, United, United States Food, Drug Administration, FDA, European Medicines Agency, Healthcare, Agency Locations: United States, United Kingdom
Total: 25